Please note that UPSpace will be unavailable from Friday, 2 May at 18:00 (South African Time) until Sunday, 4 May at 20:00 due to scheduled system upgrades. We apologise for any inconvenience this may cause and appreciate your understanding.
dc.contributor.author | Sathekge, Mike Machaba![]() |
|
dc.contributor.author | Morgenstern, Alfred![]() |
|
dc.date.accessioned | 2024-10-22T08:49:05Z | |
dc.date.issued | 2024-04 | |
dc.description.abstract | No abstract available. | en_US |
dc.description.department | Nuclear Medicine | en_US |
dc.description.embargo | 2025-02-20 | |
dc.description.librarian | hj2024 | en_US |
dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
dc.description.uri | http://link.springer.com/journal/259 | en_US |
dc.identifier.citation | Sathekge, M., Morgenstern, A. Advances in targeted alpha therapy of cancer. European Journal of Nuclear Medicine and Molecular Imaging 51, 1205–1206 (2024). https://doi.org/10.1007/s00259-024-06658-1. | en_US |
dc.identifier.issn | 1619-7070 (print) | |
dc.identifier.issn | 1619-7089 (online) | |
dc.identifier.other | 10.1007/s00259-024-06658-1 | |
dc.identifier.uri | http://hdl.handle.net/2263/98701 | |
dc.language.iso | en | en_US |
dc.publisher | Springer | en_US |
dc.rights | © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. The original publication is available at : http://link.springer.comjournal/259. | en_US |
dc.subject | Targeted alpha therapy | en_US |
dc.subject | Cancer | en_US |
dc.subject | SDG-03: Good health and well-being | en_US |
dc.subject | Editorial | en_US |
dc.title | Advances in targeted alpha therapy of cancer | en_US |
dc.type | Postprint Article | en_US |